De Souza R J, Goodwin G M, Green A R, Heal D J
Br J Pharmacol. 1986 Oct;89(2):377-84. doi: 10.1111/j.1476-5381.1986.tb10270.x.
The effects of chronic (14 day) administration to mice of the 5-HT1 agonists 8-hydroxy 2-(di-n-propylamino) tetralin (8-OH-DPAT) and 5-methoxy-3 (1,2,3,6-tetrahydropyridin-4-yl) IH indole (RU 24969) on the hypothermic response to 8-OH-DPAT and the locomotor response to RU 24969 have been examined. Chronic administration of 8-OH-DPAT (5 mg kg-1, s.c.) resulted in an attenuated hypothermic response to this drug given subcutaneously (s.c.) or intracerebroventricularly (i.c.v.) but did not alter the locomotor response to RU 24969. Chronic injection of RU 24969 (3 mg kg-1, i.p.) produced an attenuated locomotor response to this drug given i.p. or i.c.v. but not the hypothermic response to 8-OH-DPAT (0.5 mg kg-1, s.c.). Chronic administration of the putative presynaptic 5-HT1 antagonist isapirone (10 mg kg-1, i.p.) decreased the hypothermic response following 8-OH-DPAT injection but did not alter RU 24969-induced locomotion. Chronic treatment with 8-OH-DPAT (5 mg kg-1, s.c.) produced a modest enhancement of the 5-HT2 receptor-mediated head-twitch behaviour initiated by 5-hydroxytryptophan injection while chronic isapirone decreased this behavioural response. 5-HT2 receptor number in frontal cortex was unaltered by isapirone treatment but markedly decreased (34%) by chronic 8-OH-DPAT. These data suggest that chronic administration of the 5-HT1 agonists induces tolerance in their respective responses but not cross-tolerance, while chronic isapirone may down-regulate the 5-HT1A site in a matter analogous to that seen by 5-HT2 receptors following 5-HT2 receptor antagonists. 7 The data further demonstrate that chronic treatment with 8-OH-DPAT and isapirone alter postsynaptic 5-HT2 receptor function although 5-HT2 receptor number in the frontal cortex did not correlate with the behavioural change.
已研究了5-羟色胺1(5-HT1)激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)和5-甲氧基-3-(1,2,3,6-四氢吡啶-4-基)吲哚(RU 24969)对小鼠进行慢性(14天)给药后,小鼠对8-OH-DPAT的体温过低反应以及对RU 24969的运动反应的影响。对小鼠皮下注射(s.c.)8-OH-DPAT(5毫克/千克)进行慢性给药,导致小鼠对皮下或脑室内(i.c.v.)注射该药物的体温过低反应减弱,但未改变对RU 24969的运动反应。对小鼠腹腔注射(i.p.)RU 24969(3毫克/千克)进行慢性注射,导致小鼠对腹腔或脑室内注射该药物的运动反应减弱,但未改变对皮下注射8-OH-DPAT(0.5毫克/千克)的体温过低反应。对小鼠腹腔注射假定的突触前5-HT1拮抗剂伊沙匹隆(10毫克/千克)进行慢性给药,可降低注射8-OH-DPAT后的体温过低反应,但不改变RU 24969诱导的运动。对小鼠皮下注射8-OH-DPAT(5毫克/千克)进行慢性治疗,可适度增强由注射5-羟色氨酸引发的5-HT2受体介导的头部抽搐行为,而慢性注射伊沙匹隆则可降低这种行为反应。伊沙匹隆治疗未改变额叶皮质中的5-HT2受体数量,但慢性注射8-OH-DPAT可使其显著减少(34%)。这些数据表明,慢性给予5-HT1激动剂可诱导对其各自反应的耐受性,但不存在交叉耐受性,而慢性注射伊沙匹隆可能会以类似于5-HT2受体拮抗剂作用后5-HT2受体所见的方式下调5-HT1A位点。这些数据进一步证明,用8-OH-DPAT和伊沙匹隆进行慢性治疗会改变突触后5-HT2受体功能,尽管额叶皮质中的5-HT2受体数量与行为变化无关。